Literature DB >> 24761980

Successful treatment with L-asparaginase-based regimen for primary pulmonary NK/T cell lymphoma: a case report and review of the literature.

Wei Gui1, Bin Yang1, Quanliang Shen2, Min Bai1, Jun Wang1, Tao Guan1, Jin Zhao1, Jingrong Wang1, Liping Su1.   

Abstract

OBJECTIVE: To evaluate the treatment of primary pulmonary NK/T cell lymphoma.
METHOD: A case report and review of the literature. The tissue material was obtained by transbronchial biopsy, and the diagnosis was confirmed by pathology. He received five cycles of chemotherapy with L-asparaginase-based regimen. RESULT: He remained complete remission for 2 years following the initial diagnosis.
CONCLUSION: Primary pulmonary NK/T cell lymphoma is an aggressive disease. It is usually associated with poor outcome in the literature. L-asparaginase based regimen was effective for our newly diagnosed patient.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  L-asparaginase; primary pulmonary NK/T cell lymphoma; prognosis; treatment

Mesh:

Substances:

Year:  2014        PMID: 24761980     DOI: 10.1111/crj.12156

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  4 in total

1.  Primary pulmonary NK/T-cell lymphoma: A case report and literature review.

Authors:  Yajuan Qiu; Junna Hou; Dexun Hao; Dandan Zhang
Journal:  Mol Clin Oncol       Date:  2018-04-24

2.  [Clinical analyses of 24 patients with primary pulmonary NK/T-cell lymphoma].

Authors:  Y J Qiu; M Z Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

Review 3.  Primary pulmonary extranodal NK/T-cell lymphoma of nasal type misdiagnosed as pneumonia: A case report and literature review.

Authors:  Juan Zhang; MaoJuan Wang; XiaoDong Yang; Chang Liu; Xin He
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

4.  Late diagnosis: a case of rapidly progressive extranodal NK/T cell lymphoma, nasal type.

Authors:  Hiroyuki Mori; Kei Ebisawa; Mitsushige Nishimura; Kenji Kanazawa
Journal:  BMJ Case Rep       Date:  2018-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.